Intravenous versus subcutaneous immunoglobulin therapy in multifocal motor neuropathy

2012 ◽  
Author(s):  
F. Eftimov
Keyword(s):  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Subcutaneous Immunoglobulin

Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report

2010 ◽  
Vol 31 (6) ◽  
pp. 829-831 ◽  
Author(s):  
Patrizia Dacci ◽  
Nilo Riva ◽  
Marina Scarlato ◽  
Irmgard Andresen ◽  
DirkSteffen Schmidt ◽  
...  
Keyword(s):  
Case Report ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Subcutaneous Immunoglobulin

Subcutaneous immunoglobulin therapy for multifocal motor neuropathy

2009 ◽  
Vol 14 (2) ◽  
pp. 93-100 ◽  
Author(s):  
Filip Eftimov ◽  
Marinus Vermeulen ◽  
Rob J. de Haan ◽  
Leonard H. van den Berg ◽  
Ivo N. van Schaik
Keyword(s):  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Subcutaneous Immunoglobulin

Multifocal motor neuropathy: Long-term treatment with subcutaneous immunoglobulin

2021 ◽  
Vol 429 ◽  
pp. 117814
Author(s):  
Luca Gentile ◽  
Massimo Russo ◽  
Carmelo Rodolico ◽  
Ilenia Arimatea ◽  
Giuseppe Vita ◽  
...  
Keyword(s):  
Multifocal Motor Neuropathy ◽  
Term Treatment ◽  
Motor Neuropathy ◽  
Subcutaneous Immunoglobulin ◽  
Long Term Treatment

Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review

2019 ◽  
Vol 14 (1) ◽  
pp. 3-13 ◽  
Author(s):  
Ahmed Abbas ◽  
Yusuf A. Rajabally.
Keyword(s):  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Kidney Injury ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Evidence Base ◽  
Motor Neuropathy ◽  
Inflammatory Neuropathy ◽  
Inflammatory Neuropathies ◽  
Delayed Complications ◽  
Associated Risk Factors

Background: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. Discussion and Conclusion: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.

Sign in / Sign up

Export Citation Format

Share Document